Related Experiment Video
Updated: Jun 27, 2026

Oncogene Expression Analysis with Alterations in pH in a Pancreatic Ductal Cell Line
Published on: April 11, 2025
Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells
Takashi Kumagai1, Tadayuki Akagi, Julian C Desmond
1Division of Hematology and Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, CA, USA. kumamed1_2001@yahoo.co.jp
Abstract:
Molecular-targeted therapy is a hopeful approach for pancreatic cancer. Silencing of tumor suppressor genes can occur by histone deacetylation and/or DNA methylation in the promoter. Here, we identified epigenetically silenced genes in pancreatic cancer cells. Pancreatic cancer cell line, PANC-1 cells were treated either with or without 5Aza-dC (a DNA methyltransferase inhibitor) and suberoylanilide hydroxamic acid (SAHA, a histone deacetylase inhibitor), and mRNA was isolated from these cells. Oligonucleotide microarray analysis revealed that 30 genes including UCHL1, C/EBPalpha, TIMP2 and IRF7 were up-regulated after treatment with 5Aza-dC and SAHA in PANC-1. The induction of these 4 genes was validated by real-time PCR in several pancreatic cancer cell lines. Interestingly, expression of C/EBPalpha was significantly restored in 6 of 6 pancreatic cancer cell lines. Chromatin immunoprecipitation assay revealed that histone H3 of the promoter region of C/EBPalpha was acetylated in PANC-1 treated with SAHA; and bisulfate sequencing showed methylation of its promoter region in several pancreatic cancer cell lines. Forced expression of C/EBPalpha markedly suppressed clonal proliferation of PANC-1 cells. Co-immunoprecipitation assay showed the interaction of C/EBPalpha and E2F1; and the interaction caused the inhibition of E2F1 transcriptional activity. Immunohistochemical analysis revealed that C/EBPalpha localized in the cytoplasm in pancreatic adenocarcinoma cells, whereas it localized predominantly in the nucleus in normal pancreatic cells. Our data demonstrated that aberrant silencing, as well as, inappropriate cytoplasmic localization of C/EBPalpha causes dysregulation of its function, suggesting that C/EBPalpha is a novel candidate tumor suppressor gene in pancreatic cancer cells.
Insights
Epigenetic silencing of the C/EBPalpha gene contributes to pancreatic cancer progression. Restoring C/EBPalpha expression suppressed tumor cell proliferation, identifying it as a potential therapeutic target for pancreatic cancer.
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Pancreatic cancer is a challenging disease with limited therapeutic options.
- Epigenetic modifications, including DNA methylation and histone deacetylation, are key mechanisms for tumor suppressor gene silencing in cancer.
- Identifying epigenetically silenced genes is crucial for developing novel molecular-targeted therapies for pancreatic cancer.
Purpose of the Study:
- To identify epigenetically silenced genes in pancreatic cancer cells.
- To investigate the role of C/EBPalpha as a potential tumor suppressor gene in pancreatic cancer.
- To explore the therapeutic potential of targeting epigenetic silencing in pancreatic cancer.
Main Methods:
- Pancreatic cancer cells (PANC-1) were treated with DNA methyltransferase inhibitor (5Aza-dC) and histone deacetylase inhibitor (SAHA).
- Oligonucleotide microarray and real-time PCR were used to identify and validate gene expression changes.
- Chromatin immunoprecipitation, bisulfate sequencing, co-immunoprecipitation, and immunohistochemistry were employed to study C/EBPalpha regulation and function.
Main Results:
- Treatment with 5Aza-dC and SAHA upregulated several genes, including C/EBPalpha, in pancreatic cancer cells.
- C/EBPalpha expression was restored in multiple pancreatic cancer cell lines, with evidence of promoter hypomethylation and histone acetylation.
- Forced expression of C/EBPalpha suppressed pancreatic cancer cell proliferation and inhibited E2F1 transcriptional activity.
- C/EBPalpha exhibited aberrant cytoplasmic localization in pancreatic cancer cells compared to nuclear localization in normal cells.
Conclusions:
- Aberrant epigenetic silencing and inappropriate cytoplasmic localization of C/EBPalpha contribute to its functional dysregulation in pancreatic cancer.
- C/EBPalpha acts as a novel candidate tumor suppressor gene in pancreatic cancer.
- Targeting epigenetic modifications to restore C/EBPalpha function presents a promising therapeutic strategy for pancreatic cancer.
Related Concept Videos
Cell Specific Gene Expression
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Master Transcription Regulators
Abnormal Proliferation
Mitogens and the Cell Cycle

